Utilization and Costs of Severe Uncontrolled Asthma in a Managed-Care Setting

Journal of Allergy and Clinical Immunology: In Practice

Volumn 4, Issue 1, 2016, Pages 120-129.e3

  Zeiger, Robert S ^a   Schatz, Michael ^a   Dalal, Anand A ^b   Qian, Lei ^a   Chen, Wansu ^a   Ngor, Eunice W ^a   Suruki, Robert Y ^b   Kawatkar, Aniket A ^a  

^a KAISER PERMANENTE   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Antiasthma agents; Asthma control; Asthma cost; Asthma guidelines; Asthma impairment; Asthma risk; Controller medication; Persistent asthma; Severe asthma

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LONG ACTING DRUG; MEPOLIZUMAB; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT;

AGE DISTRIBUTION; ANXIETY; ARTICLE; ASTHMA; CHILD; CHRONIC SINUSITIS; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG COST; DRUG MEGADOSE; ETHNIC DIFFERENCE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HOSPITALIZATION; HUMAN; ICD-9; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MANAGED CARE; MEDICAL INFORMATION; MEDICAL SPECIALIST; MONOTHERAPY; MULTIVARIATE ANALYSIS; NONLINEAR REGRESSION ANALYSIS; NOSE POLYP; OBESITY; OBSERVATIONAL STUDY; ONLINE SYSTEM; PATIENT COMPLIANCE; PNEUMONIA; PRESCHOOL CHILD; RESPIRATORY TRACT INFECTION; RHINITIS; SCHOOL CHILD; SEVERE UNCONTROLLED ASTHMA; UNIVARIATE ANALYSIS; ADOLESCENT; ADULT; DISEASE COURSE; ECONOMICS; HEALTH INSURANCE; INTERNATIONAL CLASSIFICATION OF DISEASES; RECURRENT DISEASE; STATISTICS AND NUMERICAL DATA; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADULT; ASTHMA; DISEASE PROGRESSION; HEALTH CARE COSTS; HUMANS; INTERNATIONAL CLASSIFICATION OF DISEASES; MANAGED CARE PROGRAMS; RECURRENCE; UNITED STATES; YOUNG ADULT;

EID: 84953838542     PISSN: 22132198     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaip.2015.08.003     Document Type: Article

References (40)

1. Wenzel S.E., Busse W.W. Severe asthma: lessons from the Severe Asthma Research Program. J Allergy Clin Immunol 2007, 119:14-21.
2. Hekking P.P., Wener R.R., Amelink M., Zwinderman A.H., Bouvy M.L., Bel E.H. The prevalence of severe refractory asthma. J Allergy Clin Immunol 2015, 135:896-902.
3. Bahadori K., Doyle-Waters M.M., Marra C., Lynd L., Alasaly K., Swiston J., et al. Economic burden of asthma: a systematic review. BMC Pulm Med 2009, 9:24.
4. Proceedings of the ATS Workshop on Refractory Asthma Current Understanding, Recommendations, and Unanswered Questions. Am J Respir Crit Care Med 2000, 162:2341-2351.
5. Bousquet J., Mantzouranis E., Cruz A.A., Ait-Khaled N., Baena-Cagnani C.E., Bleecker E.R., et al. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol 2010, 126:926-938.
6. Moore W.C., Meyers D.A., Wenzel S.E., Teague W.G., Li H., Li X., et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010, 181:315-323.
7. Fitzpatrick A.M., Teague W.G., Meyers D.A., Peters S.P., Li X., Li H., et al. Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program. J Allergy Clin Immunol 2011, 127:382-389.
8. Schatz M., Hsu J.W., Zeiger R.S., Chen W., Dorenbaum A., Chipps B.E., et al. Phenotypes determined by cluster analysis in severe or difficult-to-treat asthma. J Allergy Clin Immunol 2014, 133:1549-1556.
9. Newby C., Heaney L.G., Menzies-Gow A., Niven R.M., Mansur A., Bucknall C., et al. Statistical cluster analysis of the British Thoracic Society Severe refractory Asthma Registry: clinical outcomes and phenotype stability. PLoS One 2014, 9:e102987.
10. Ortega H., Li H., Suruki R., Albers F., Gordon D., Yancey S. Cluster analysis and characterization of response to mepolizumab. A step closer to personalized medicine for patients with severe asthma. Ann Am Thorac Soc 2014, 11:1011-1017.
11. Bourdin A., Molinari N., Vachier I., Varrin M., Marin G., Gamez A.S., et al. Prognostic value of cluster analysis of severe asthma phenotypes. J Allergy Clin Immunol 2014, 134:1043-1050.
12. National Committee of Quality Assurance, 2015. HEDIS and performance measures. Available from:. Accessed April 19, 2015. http://www.ncqa.org/HEDISQualityMeasurement.aspx.
13. Mosen D.M., Macy E., Schatz M., Mendoza G., Stibolt T.B., McGaw J., et al. How well do the HEDIS asthma inclusion criteria identify persistent asthma?. Am J Manag Care 2005, 11:650-654.
14. Schatz M., Zeiger R.S., Vollmer W.M., Mosen D., Mendoza G., Apter A.J., et al. The controller-to-total asthma medication ratio is associated with patient-centered as well as utilization outcomes. Chest 2006, 130:43-50.
15. Zeiger R.S., Schatz M., Li Q., Zhang F., Purdum A.S., Chen W. Step-up care improves impairment in uncontrolled asthma: an administrative data study. Am J Manag Care 2010, 16:897-906.
16. Agency for Health Research Quality, 2015. National quality measures clearinghouse. Available from:. Accessed April 19, 2015. http://www.qualitymeasures.ahrq.gov/content.aspx?id=48617.
17. Fuhlbrigge A., Peden D., Apter A.J., Boushey H.A., Camargo C.A., Gern J., et al. Asthma outcomes: exacerbations. J Allergy Clin Immunol 2012, 129(Suppl):S34-S48.
18. Schatz M., Zeiger R.S., Vollmer W.M., Mosen D., Apter A.J., Stibolt T.B., et al. Validation of a beta-agonist long-term asthma control scale derived from computerized pharmacy data. J Allergy Clin Immunol 2006, 117:995-1000.
19. Red Book, 2015. Available from:. Accessed April 19, 2015. http://sites.truvenhealth.com/redbook/index.html.
20. O'Neill S., Sweeney J., Patterson C.C., Menzies-Gow A., Niven R., Mansur A.H., et al. The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry. Thorax 2015, 70:376-378.
21. Ivanova J.I., Bergman R., Birnbaum H.G., Colice G.L., Silverman R.A., McLaurin K. Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma. J Allergy Clin Immunol 2012, 129:1229-1235.
22. Zeiger R.S., Hay J.W., Contreras R., Chen W., Quinn V.P., Seal B., et al. Asthma costs and utilization in a managed care organization. J Allergy Clin Immunol 2008, 121:885-892.
23. Pavord I.D., Korn S., Howarth P., Bleecker E.R., Buhl R., Keene O.N., et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012, 380:651-659.
24. Chanez P., Wenzel S.E., Anderson G.P., Anto J.M., Bel E.H., Boulet L.P., et al. Severe asthma in adults: what are the important questions?. J Allergy Clin Immunol 2007, 119:1337-1348.
25. von Bulow A., Kriegbaum M., Backer V., Porsbjerg C. The prevalence of severe asthma and low asthma control among Danish adults. J Allergy Clin Immunol Pract 2014, 2:759-767.
26. Household income in the United States, 2015. Available from:. Accessed April 19, 2015. http://en.wikipedia.org/wiki/Household_income_in_the_United_States.
27. Expert Panel 3 Report for the National Asthma Education Prevention Program, 2007. Available from:. Accessed April 19, 2015. http://www.nhlbi.nih.gov/files/docs/guidelines/asthgdln.pdf.
28. Zeiger R.S., Schatz M., Li Q., Chen W., Gossage D., Khaty D., et al. High blood eosinophil count is a risk factor for future asthma exacerbations in adult persistent asthma. J Allergy Clin Immunol Pract 2014, 2:741-750.
29. Schatz M., Zeiger R.S., Yang S.J., Weinstein A.G., Chen W., Saris-Baglama R.N., et al. Development and preliminary validation of the Adult Asthma Adherence Questionnaire. J Allergy Clin Immunol Pract 2013, 1:280-288.
30. Schatz M., Meckley L.M., Kim M., Stockwell B.T., Castro M. Asthma exacerbation rates in adults are unchanged over a 5-year period despite high-intensity therapy. J Allergy Clin Immunol Pract 2014, 2:570-574.
31. Hasegawa K., Sullivan A.F., Tovar H.E., Gaeta T.J., Fee C., Turner S.J., et al. A multicenter observational study of US adults with acute asthma: who are the frequent users of the emergency department?. J Allergy Clin Immunol Pract 2014, 2:733-740.
32. Calhoun W.J., Haselkorn T., Mink D.R., Miller D.P., Dorenbaum A., Zeiger R.S. Clinical burden and predictors of asthma exacerbations in patients on guideline-based steps 4-6 asthma therapy in the TENOR cohort. J Allergy Clin Immunol Pract 2014, 2:193-200.
33. Briggs A.H., Bousquet J., Wallace M.V., Busse W.W., Clark T.J., Pedersen S.E., et al. Cost-effectiveness of asthma control: an economic appraisal of the GOAL study. Allergy 2006, 61:531-536.
34. Zeiger R.S., Schatz M., Li Q., Solari P.G., Zazzali J.L., Chen W. Real-time asthma outreach reduces excessive short-acting beta2-agonist use: a randomized study. J Allergy Clin Immunol Pract 2014, 2:445-456.
35. Sullivan P.W., Ghushchyan V.H., Slejko J.F., Belozeroff V., Globe D.R., Lin S.L. The burden of adult asthma in the United States: evidence from the Medical Expenditure Panel Survey. J Allergy Clin Immunol 2011, 127:363-369.
36. Barnett S.B., Nurmagambetov T.A. Costs of asthma in the United States: 2002-2007. J Allergy Clin Immunol 2011, 127:145-152.
37. Rank M.A., Liesinger J.T., Ziegenfuss J.Y., Branda M.E., Lim K.G., Yawn B.P., et al. Asthma expenditures in the United States comparing 2004 to 2006 and 1996 to 1998. Am J Manag Care 2012, 18:499-504.
38. Van G.E., Laforest L., Pietri G., Boissel J.P., Gormand F., Ben-Joseph R., et al. Persistent asthma: disease control, resource utilisation and direct costs. Eur Respir J 2002, 20:260-267.
39. Akinbami L.J., Sullivan S.D., Campbell J.D., Grundmeier R.W., Hartert T.V., Lee T.A., et al. Asthma outcomes: healthcare utilization and costs. J Allergy Clin Immunol 2012, 129(Suppl):S49-S64.
40. Fishman P.A., Hornbrook M.C. Assigning resources to health care use for health services research: options and consequences. Med Care 2009, 47(Suppl 1):S70-S75.